|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
GeneticVariation |
LHGDN |
Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex.
|
19098025 |
2009 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
GeneticVariation |
LHGDN |
However, we show for the first time that HLA-DRB1*15 allele modulates the course of MS for relapsing-remitting (RR) onset patients likely by precipitating the secondary progressive (SP) phase.
|
18615093 |
2008 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
GeneticVariation |
LHGDN |
To explore whether the relative rarity of MS in Malta might be the result of lower population frequencies of major histocompatibility complex susceptibility alleles, we genotyped the HLA-DRB1 locus in 77 Maltese-born patients (97% of the prevalent unrelated native cases) and 206 Maltese controls.
|
18057318 |
2008 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
GeneticVariation |
LHGDN |
Genotyping of HLA-DRB1 and -DPB1 alleles was performed in 121 consecutive Japanese patients with clinically definite MS based on the Poser criteria and 125 healthy controls.
|
18952831 |
2008 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
Biomarker |
LHGDN |
HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis.
|
18656179 |
2008 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
Biomarker |
LHGDN |
Although significant associations with both HLA-DRB1 and HLA-DRB5 loci were present, HLA-DRB1*1503 was associated with MS in the absence of HLA-DRB5, providing evidence for HLA-DRB1 as the primary susceptibility gene.
|
18832704 |
2008 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
Biomarker |
LHGDN |
A significant over transmission of HLA-DRB1*15 from mothers was observed (chi (2) = 7.73, P = 0.0054), suggesting that parent of origin effects at the MHC determine susceptibility to MS.
|
17972102 |
2008 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
GeneticVariation |
LHGDN |
We show here that HLA-DRB1*15-bearing-haplotypes in 1970 individuals from 494 MS families are indeed heterogeneous.
|
18765817 |
2008 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
Biomarker |
LHGDN |
Multiple sclerosis immunopathic trait and HLA-DR(2)15 as independent risk factors in multiple sclerosis.
|
17463066 |
2007 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
GeneticVariation |
LHGDN |
A genome-wide scan in forty large pedigrees with multiple sclerosis.
|
18000641 |
2007 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
GeneticVariation |
LHGDN |
In Caucasian populations of Northern European descent, the DR15 haplotype (DRB1*1501-DQA1*0102-DQB1*0602) has been hypothesized to be the primary HLA genetic susceptibility factor for MS.
|
17329717 |
2007 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
Biomarker |
LHGDN |
Taking into account that the response to immunomodulator drugs for MS treatment changes according to the DRB1*1501 allele and African-American MS patients presented poor response to the interferons, phenotype heterogeneity of HLA loci found in this study could influence therapeutic decisions in the Brazilian MS population.
|
17489940 |
2007 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
GeneticVariation |
LHGDN |
The low frequency of the disease-associated DRB1*15-DQB1*06 haplotype in the Sami population may contribute to the low prevalence of MS in Sami, in addition to other yet unidentified genetic and environmental factors.
|
17389012 |
2007 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
GeneticVariation |
LHGDN |
Genotyping sets of benign and malignant MS patients showed that HLA-DRB1*01 was significantly underrepresented in malignant compared with benign cases.
|
18087043 |
2007 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
GeneticVariation |
LHGDN |
To determine whether BTNL2 contributes to MS, we genotyped 1136 well-characterized MS families from the UK and the USA, as well as an African-American case-control data set, making this among the largest genetic studies in MS. Family-based and case-control association studies were performed for the BTNL2 and HLA-DRB1 loci.
|
16321988 |
2006 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
GeneticVariation |
LHGDN |
These results indicate that the difference in risk association with MS of DRB1*1501 versus DRB1*1502 is not due to a lack of antigen presentation by DRB1*1502, at least for this set of myelin peptides, and suggest that other mechanisms involving DRB1*1501 may account for increased susceptibility to MS.
|
15372502 |
2004 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
GeneticVariation |
LHGDN |
A selective association with HLA-DRB1*15 was revealed, indicating a primary role for the DRB1 locus in MS independent of DQB1*0602.
|
14669136 |
2004 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
GeneticVariation |
LHGDN |
In addition, we found that the class I/extended class I region, defined by a genomic segment of approximately 400 kb between MOGCA and D6S265, harbors genes that independently increase risk of, or provide protection from, MS. Log-linear modeling analysis of constituent haplotypes that represent genomic regions containing class I (MOGCA-D6S265), class III (TNFa-TNFd-D6S273), and class II (DRB1-DQB1) genes indicated that having class I and class II susceptibility variants on the same haplotype provides an additive effect on risk.
|
11923913 |
2002 |
|
HLA-DRB1
|
Multiple Sclerosis
|
0.500 |
GeneticVariation |
LHGDN |
It remains possible that the association of MS with HLA-DRB1*15 is due to linkage disequilibrium with a nearby locus and/or to the presence of disease-influencing allele(s) in DRB1*15-negative haplotypes.
|
11519010 |
2001 |